NCT05667129View on ClinicalTrials.gov

A Phase 1 Study to Evaluate Safety and Tolerability of Single and Multiple Ascending Doses of XEN-101

PHASE1CompletedINTERVENTIONAL

Enrollment

97

Participants

Timeline

Start Date

December 1, 2022

Primary Completion Date

May 30, 2023

Study Completion Date

May 30, 2023

Conditions

Healthy

Interventions

DRUG

XEN-101

Capsule formulation

DRUG

Placebo

capsule formulation

Trial Locations (1)

Unknown

CRU Hungary - Early Phase Unit, Kistarcsa

Sponsors

Lead Sponsor

Xeno Biosciences

All Listed Sponsors

lead

Xeno Biosciences

INDUSTRY

NCT05667129 - A Phase 1 Study to Evaluate Safety and Tolerability of Single and Multiple Ascending Doses of XEN-101 | Biotech Hunter | Biotech Hunter